Cochrane · systematic review · CD003895
Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease in dialysis patients
Hahn, D, Cody, JD, Hodson, EM · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
21
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 12.5%Very low 0 · 0%Low 5 · 20.8%Moderate 10 · 41.7%High 6 · 25%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
CERA versus other ESA for the anaemia of end‐stage kidney disease in dialysis patients
Population: patients with the anaemia of end‐stage kidney disease undergoing dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Final Hb g/dL: CERA every 2 weeks versus rHuEPO CERA vs other ESA | no estimate extracted | 4 studies · 1126 participants | High |
Final Hb g/dL: CERA every 4 week versus rHuEPO CERA vs other ESA | no estimate extracted | 2 studies · 672 participants | High |
Final Hb g/dL: CERA every 2 week versus darbepoetin CERA vs other ESA | no estimate extracted | 1 study · 249 participants | Moderate Downgraded: imprecision, inconsistency |
All‐cause mortality: CERA every 2 weeks versus rHuEPO CERA vs other ESA | RR 1.03 [0.67, 1.57] | 4 studies · 1341 participants | Moderate Downgraded: imprecision, inconsistency |
Transfusions: CERA every 2 weeks versus rHuEPO CERA vs other ESA | RR 0.92 [0.64, 1.32] | 4 studies · 1341 participants | Moderate Downgraded: imprecision, inconsistency |
Numbers of adverse events due to hypertension: CERA every 2 weeks versus rHuEPO CERA vs other ESA | RR 0.93 [0.69, 1.26] | 4 studies · 1341 participants | High |
Numbers of adverse events due to access thrombosis: CERA every 2 weeks versus rHuEPO CERA vs other ESA | RR 0.96 [0.56, 1.65] | 4 studies · 1341 participants | Moderate Downgraded: imprecision, inconsistency |
Different frequencies of CERA for the anaemia of end‐stage kidney disease in dialysis patients
Population: patients with the anaemia of end‐stage kidney disease undergoing dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Final Hb (g/dL) | no estimate extracted | 2 studies · 675 participants | Moderate Downgraded: inconsistency |
All‐cause mortality | RR 1.03 [0.6, 1.78] | 2 studies · 822 participants | High |
Transfusion | RR 1.11 [0.52, 2.37] | 2 studies · 822 participants | Moderate Downgraded: inconsistency |
Numbers of adverse effects due to hypertension | RR 1.18 [0.83, 1.67] | 2 studies · 822 participants | High |
Numbers of adverse events due to access thrombosis | RR 0.96 [0.64, 1.43] | 2 studies · 822 participants | High |
Darbepoetin versus rHuEPO for the anaemia of end‐stage kidney disease in dialysis patients
Population: patients with the anaemia of end‐stage kidney disease in dialysis patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Final/change in Hb (g/dL) Darbepoetin vs rHuEPO | no estimate extracted | 6 studies · 1245 participants | Moderate Downgraded: risk of bias, inconsistency |
Final/change in ESA dose Darbepoetin vs rHuEPO | no estimate extracted | 3 studies · 757 participants | Low Downgraded: risk of bias, inconsistency |
All‐cause mortality Darbepoetin vs rHuEPO | RR 1.29 [0.82, 2.02] | 5 studies · 1596 participants | Moderate Downgraded: risk of bias, inconsistency |
Total treatment‐related adverse events Darbepoetin vs rHuEPO | no estimate extracted | 3 studies · 570 participants | Ungraded |
Hypertension Darbepoetin vs rHuEPO | no estimate extracted | 4 studies · 1475 participants | Low Downgraded: risk of bias, inconsistency |
Access thrombosis/vascular complication Darbepoetin vs rHuEPO | no estimate extracted | 4 studies · 1475 participants | Moderate Downgraded: risk of bias, inconsistency |
Transfusion Darbepoetin vs rHuEPO | no estimate extracted | 3 studies · 1069 participants | Moderate Downgraded: risk of bias, inconsistency |
rHuEPO once/week versus rHuEPO 2 to 3 times/week for the anaemia of end‐stage kidney disease in dialysis patients
Population: patients with the anaemia of end‐stage kidney disease undergoing dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Final/change in Hb rHuEPO once/week vs rHuEPO 2 to 3 times/week | no estimate extracted | 7 studies · 363 participants | Low Downgraded: risk of bias |
Final/change in EPO dose rHuEPO once/week vs rHuEPO 2 to 3 times/week | no estimate extracted | 5 studies · 217 participants | Low Downgraded: risk of bias |
Adverse effects: transfusions rHuEPO once/week vs rHuEPO 2 to 3 times/week | no estimate extracted | 1 study · 173 participants | Ungraded |
Adverse effects: hypertension rHuEPO once/week vs rHuEPO 2 to 3 times/week | no estimate extracted | 4 studies · 175 participants | Low Downgraded: risk of bias |
Adverse effects: access problems rHuEPO once/week vs rHuEPO 2 to 3 times/week | no estimate extracted | 1 study · 173 participants | Ungraded |